Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit
Chemomab Therapeutics (Nasdaq: CMMB), a clinical stage biotech company focused on fibro-inflammatory diseases, announces its participation in Oppenheimer's Movers in Rare Disease Summit on December 12, 2024, at the Westin Grand Central in New York City. The invitation-only event will showcase companies with potential near-term stock-moving catalysts through panels, presentations, and one-on-one investor meetings. Chemomab's management will deliver an Elevator Pitch at 2:45-3:30 pm EST and will be available for individual meetings with registered attendees.
Chemomab Therapeutics (Nasdaq: CMMB), un'azienda biotech in fase clinica focalizzata sulle malattie fibro-infiammatorie, annuncia la sua partecipazione al Summit di Oppenheimer sui Movers nelle Malattie Rare il 12 dicembre 2024, presso il Westin Grand Central di New York City. L'evento, su invito esclusivo, presenterà aziende con potenziali catalizzatori in grado di influenzare il mercato azionario nel breve termine attraverso pannelli, presentazioni e incontri individuali con gli investitori. La direzione di Chemomab presenterà un Elevator Pitch dalle 14:45 alle 15:30 EST e sarà disponibile per incontri individuali con i partecipanti registrati.
Chemomab Therapeutics (Nasdaq: CMMB), una empresa biotecnológica en etapa clínica centrada en enfermedades fibro-inflamatorias, anuncia su participación en el Summit de Oppenheimer sobre Movers en Enfermedades Raras el 12 de diciembre de 2024, en el Westin Grand Central de Nueva York. El evento, solo por invitación, mostrará a empresas con posibles catalizadores que podrían mover las acciones a corto plazo a través de paneles, presentaciones y reuniones individuales con inversionistas. La dirección de Chemomab dará una presentación de Elevator Pitch de 14:45 a 15:30 EST y estará disponible para reuniones individuales con los asistentes registrados.
Chemomab Therapeutics (Nasdaq: CMMB), 섬유-염증 질환에 초점을 맞춘 임상 단계의 생명공학 회사는 2024년 12월 12일 뉴욕시의 웨스틴 그랜드 센트럴에서 열리는 오펜하이머 희귀질환 서밋에 참여한다고 발표했습니다. 초대받은 인원만 참석할 수 있는 이 행사는 패널, 발표 및 일대일 투자자 회의를 통해 단기 주식 움직임을 유발할 수 있는 잠재력을 가진 기업들을 소개할 것입니다. Chemomab의 경영진은 동부 표준시 기준으로 오후 2시 45분부터 3시 30분까지 엘리베이터 피치를 진행하고, 등록된 참석자와 개별 미팅을 가질 예정입니다.
Chemomab Therapeutics (Nasdaq: CMMB), une entreprise biopharmaceutique en phase clinique spécialisée dans les maladies fibro-inflammatoires, annonce sa participation au Sommet d'Oppenheimer sur les Movers dans les Maladies Rares qui se déroulera le 12 décembre 2024, au Westin Grand Central de New York. Cet événement sur invitation uniquement mettra en avant des entreprises avec des catalyseurs potentiels pouvant influencer le marché boursier à court terme, via des panels, des présentations et des réunions individuelles avec des investisseurs. La direction de Chemomab présentera un Elevator Pitch de 14h45 à 15h30 EST et sera disponible pour des réunions individuelles avec les participants inscrits.
Chemomab Therapeutics (Nasdaq: CMMB), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf fibro-inflammatorische Erkrankungen konzentriert, gibt die Teilnahme an dem Oppenheimer Summit zu Movers in der seltenen Erkrankung am 12. Dezember 2024 im Westin Grand Central in New York City bekannt. Die Einladung zu dieser Veranstaltung erfolgt nur auf Einladung und wird Unternehmen präsentieren, die kurzfristige Aktienbewegungen durch Podiumsdiskussionen, Präsentationen und persönliche Investorenmeetings ermöglichen könnten. Das Management von Chemomab wird von 14:45 bis 15:30 Uhr EST einen Elevator Pitch halten und steht für individuelle Meetings mit registrierten Teilnehmern zur Verfügung.
- None.
- None.
—Movers in Rare Disease Summit Will Include Elevator Pitches from Rare Disease Companies
with “Key, Near-Term, Potentially Stock-Moving Catalysts”—
TEL AVIV, Israel, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that it will participate in Oppenheimer's Movers in Rare Disease Summit on Thursday, December 12, 2024, at the Westin Grand Central in New York City. The invitation-only Rare Disease Summit will feature a day of panels, presentations and 1-on-1 investor meetings with companies working in the rare disease space.
Chemomab management will present an Elevator Pitch and will be available for one-on-one meetings with registered attendees.
Oppenheimer Movers in Rare Disease Summit
Date: December 12, 2024
Time of Elevator Pitch: 2:45-3:30 pm EST
Location: Westin Grand Central, New York, NY
Format: Elevator Pitch & 1x1 Meetings
Please contact your Oppenheimer representative to register for the Rare Disease Summit and to schedule a 1x1 meeting with Chemomab management.
About Chemomab Therapeutics Ltd.
Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a first-in-class dual activity monoclonal antibody that neutralizes CCL24 and has demonstrated disease-modifying potential. In clinical and preclinical studies, CM-101 has been shown to have a favorable safety profile and has been generally well-tolerated, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Chemomab has reported positive results from four clinical trials of CM-101 in patients. Based on recent promising data from its Phase 2 SPRING trial in the rare liver disease primary sclerosing cholangitis (PSC), the company expects two milestones in early 2025 -- FDA feedback on the design of its planned CM-101 PSC registrational trial and data from the SPRING trial open label extension. CM-101 has received FDA and EMA Orphan Drug and FDA Fast Track designations for the treatment of PSC. Chemomab’s CM-101 program for the treatment of systemic sclerosis is Phase 2-ready with an open U.S. IND. For more information, visit: chemomab.com.
Contacts:
Media and Investors:
Barbara Lindheim
Consulting Vice President, Investor & Public Relations,
Strategic Communications
Phone: +1 917-355-9234
barbara.lindheim@chemomab.com
IR@chemomab.com
FAQ
When is Chemomab (CMMB) presenting at Oppenheimer's Rare Disease Summit 2024?
What type of companies are featured at Oppenheimer's 2024 Rare Disease Summit?
How can investors meet with Chemomab (CMMB) management at the Oppenheimer summit?
What is the format of Chemomab's (CMMB) participation at the Oppenheimer summit?
